Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 28 entries
View as:

A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)

Phase: N/A Priority: Normal
NCT ID: NCT02653391 Org: User:
Start: 02/29/16 End: 12/31/18 Due: 12/31/19

A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT03098797 Org: User:
Start: 07/05/17 End: 10/11/21 Due: 10/11/22

A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Optic Neuropathy

Phase: N/A Priority: Normal
NCT ID: NCT02693119 Org: User:
Start: 03/31/16 End: 12/31/19 Due: 12/31/20

A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Bendavia™ (MTP-131) in Patients With Heart Failure

Phase: N/A Priority: Normal
NCT ID: NCT02388529 Org: User:
Start: 05/31/15 End: 10/31/15 Due: 10/31/16

A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction

Phase: N/A Priority: Normal
NCT ID: NCT02814097 Org: User:
Start: 09/02/16 End: 06/02/17 Due: 06/02/18

A Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in Elderly

Phase: N/A Priority: Normal
NCT ID: NCT02245620 Org: User:
Start: 01/15/15 End: 07/06/16 Due: 07/06/17

A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure

Phase: N/A Priority: Normal
NCT ID: NCT02914665 Org: User:
Start: 10/20/16 End: 11/27/17 Due: 11/27/18

Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction

Phase: N/A Priority: Normal
NCT ID: NCT02788747 Org: User:
Start: 06/30/16 End: 10/31/17 Due: 10/31/18

Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study

Phase: N/A Priority: Normal
NCT ID: NCT02805790 Org: User:
Start: 08/22/16 End: 03/23/17 Due: 03/23/18

ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

Phase: N/A Priority: Normal
NCT ID: NCT06373731 Org: User:
Start: 05/30/24 End: 08/31/27 Due: 08/31/28

An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration

Phase: N/A Priority: Normal
NCT ID: NCT02848313 Org: User:
Start: 10/28/16 End: 04/10/18 Due: 04/10/19

Safety and Pharmacokinetic (PK) Study of Oral Bendavia Administered for 7 Days

Phase: N/A Priority: Normal
NCT ID: NCT01786915 Org: User:
Start: 02/28/13 End: 03/31/13 Due: 03/31/14

A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension

Phase: N/A Priority: Normal
NCT ID: NCT03323749 Org: User:
Start: 10/09/17 End: 02/10/20 Due: 02/10/21

Effects of Intravenous Bendavia™ on Reperfusion Injury in Patients Undergoing Angioplasty of the Renal Artery

Phase: N/A Priority: Normal
NCT ID: NCT01755858 Org: User:
Start: 12/31/12 End: 05/31/16 Due: 05/31/17

A Study of MTP-131 Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration

Phase: N/A Priority: Normal
NCT ID: NCT02314299 Org: User:
Start: 11/30/14 End: 06/30/15 Due: 06/30/16

A Phase 1 Study Examining the Pharmacokinetics and Tolerability of a Single Oral Dose of Bendavia (MTP-131)

Phase: N/A Priority: Normal
NCT ID: NCT01754818 Org: User:
Start: 11/30/12 End: 02/28/13 Due: 02/28/14

Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy

Phase: N/A Priority: Normal
NCT ID: NCT02367014 Org: User:
Start: 02/28/15 End: 04/30/16 Due: 04/30/17

Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)

Phase: N/A Priority: Normal
NCT ID: NCT02976038 Org: User:
Start: 12/31/16 End: 04/09/20 Due: 04/09/21

Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)

Phase: N/A Priority: Normal
NCT ID: NCT05162768 Org: User:
Start: 04/29/22 End: 10/31/24 Due: 10/31/25

A Phase 1 Study Investigating the Safety and Pharmacokinetics of Repeat-dose Intravenous Infusion of MTP-131 in Subjects With Impaired Renal Function

Phase: N/A Priority: Normal
NCT ID: NCT02436447 Org: User:
Start: 05/31/15 End: 10/31/15 Due: 10/31/16

ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA

Phase: N/A Priority: Normal
NCT ID: NCT03891875 Org: User:
Start: 03/27/19 End: 04/14/22 Due: 04/14/23

Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MTP-131 (Bendavia™) in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT01115920 Org: User:
Start: 05/31/10 End: 09/30/10 Due: 09/30/11

A Study Investigating the Safety, Tolerability, and Pharmacokinetics of MTP-131 in Subjects With Congestive Heart Failure

Phase: N/A Priority: Normal
NCT ID: NCT02388464 Org: User:
Start: 07/31/14 End: 06/30/15 Due: 06/30/16

The Impact of Intravenous Bendavia™ on Endothelial Reactivity Dysfunction in Cigarette Smoking

Phase: N/A Priority: Normal
NCT ID: NCT01518985 Org: User:
Start: 01/31/12 End: 03/31/12 Due: 03/31/13

An Observational Study of Patients With Primary Mitochondrial Disease (SPIMM-300)

Phase: N/A Priority: Normal
NCT ID: NCT03048617 Org: User:
Start: 02/13/17 End: 03/07/19 Due: 03/07/20